1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Refractory Leukemia Global Clinical Trials Review, H1, 2014

Refractory Leukemia Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Refractory Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Refractory Leukemia Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Refractory Leukemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Refractory Leukemia to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Refractory Leukemia to Oncology Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Refractory Leukemia 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Refractory Leukemia Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
Sanofi 28
Clinical Trial Overview of Sanofi 28
Otsuka Pharmaceutical Co., Ltd. 29
Clinical Trial Overview of Otsuka Pharmaceutical Co., Ltd. 29
Teva Pharmaceutical Industries Limited 30
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 30
Spectrum Pharmaceuticals, Inc. 31
Clinical Trial Overview of Spectrum Pharmaceuticals, Inc. 31
Merck and Co., Inc. 32
Clinical Trial Overview of Merck and Co., Inc. 32
Johnson and Johnson 33
Clinical Trial Overview of Johnson and Johnson 33
Bristol-Myers Squibb Company 34
Clinical Trial Overview of Bristol-Myers Squibb Company 34
BioCryst Pharmaceuticals, Inc. 35
Clinical Trial Overview of BioCryst Pharmaceuticals, Inc. 35
AEterna Zentaris Inc. 36
Clinical Trial Overview of AEterna Zentaris Inc. 36
Clinical Trial Overview of Top Institutes / Government 37
National Cancer Institute 37
Clinical Trial Overview of National Cancer Institute 37
The University of Texas M. D. Anderson Cancer Center 39
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 39
Sidney Kimmel Comprehensive Cancer Center 40
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 40
Fred Hutchinson Cancer Research Center 41
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 41
National Institutes of Health Clinical Center 42
Clinical Trial Overview of National Institutes of Health Clinical Center 42
Seattle Children's Hospital, Research and Foundation 43
Clinical Trial Overview of Seattle Children's Hospital, Research and Foundation 43
Children's Oncology Group 44
Clinical Trial Overview of Children's Oncology Group 44
Case Comprehensive Cancer Center 45
Clinical Trial Overview of Case Comprehensive Cancer Center 45
Five Key Clinical Profiles 46
Appendix 79
Abbreviations 79
Definitions 79
Research Methodology 80
Secondary Research 80
About GlobalData 81
Contact Us 81
Disclaimer 81
Source 82

List of Tables
Refractory Leukemia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Refractory Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Refractory Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Refractory Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Refractory Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Refractory Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Refractory Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Refractory Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014* 14
Refractory Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Refractory Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Refractory Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014* 17
Refractory Leukemia Therapeutics, Global, Clinical Trials by Phase, 2014* 18
Refractory Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Refractory Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Refractory Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Refractory Leukemia Therapeutics, Global, Suspended Clinical Trials, 2014* 22
Refractory Leukemia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 22
Refractory Leukemia Therapeutics, Global, Terminated Clinical Trials, 2014* 22
Refractory Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Refractory Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Refractory Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Refractory Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Refractory Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 28
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Otsuka Pharmaceutical Co., Ltd., 2014* 29
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 30
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Spectrum Pharmaceuticals, Inc., 2014* 31
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 32
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 33
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 34
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by BioCryst Pharmaceuticals, Inc., 2014* 35
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AEterna Zentaris Inc., 2014* 36
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 37
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 39
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 40
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 41
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institutes of Health Clinical Center, 2014* 42
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Seattle Children's Hospital, Research and Foundation, 2014* 43
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 44
Refractory Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 45

List of Figures
Refractory Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Refractory Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Refractory Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Refractory Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Refractory Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Refractory Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Refractory Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014* 14
Refractory Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Refractory Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Refractory Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014* 17
Refractory Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Refractory Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Refractory Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Refractory Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Refractory Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Refractory Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Refractory Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Refractory Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Refractory Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 80

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Therapy Market in the UK

  • November 2016
    11 pages
  • Therapy  

  • United Kingdom  

View report >

Cancer Statistics in Russia

  • November 2016
    8 pages
  • Leukemia  

    Cancer  

    Radiography  

  • Russian Federat...  

View report >

Related Market Segments :

Leukemia
Clinical Trial
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.